Clinical complete response after nivolumab administered as a third-line treatment for unresectable advanced gastric cancer with peritoneal dissemination: A case report

INTRODUCTION AND IMPORTANCE: Nivolumab, which is a fully human IgG4 PD-1 immune checkpoint inhibitor antibody, has been recommended as a third-line treatment based on the results of the ATTRACTION-2 study involving patients with unresectable advanced gastric cancer. CASE PRESENTATION: A 69 year-old...

Descripción completa

Detalles Bibliográficos
Autores principales: Komo, Toshiaki, Suzuki, Takahisa, Tazawa, Hirofumi, Sada, Haruki, Morimoto, Hiroshi, Shimada, Norimitsu, Hadano, Naoto, Onoe, Takashi, Sudo, Takeshi, Shimizu, Yosuke, Tashiro, Hirotaka
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8264597/
https://www.ncbi.nlm.nih.gov/pubmed/34237686
http://dx.doi.org/10.1016/j.ijscr.2021.106161

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8264597/
https://www.ncbi.nlm.nih.gov/pubmed/34237686
http://dx.doi.org/10.1016/j.ijscr.2021.106161

Ejemplares similares